Drug Profile
SAR 110894
Alternative Names: SAR110894; SAR110894DLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antidementias; Antipsychotics; Mood stabilisers
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 31 Jan 2013 Sanofi completes a phase II trial in Alzheimer's disease in US, Australia, Canada, and EU (NCT01266525)
- 11 Feb 2011 Phase-II clinical trials in Alzheimer's disease in USA (PO)
- 29 Apr 2009 Phase-I clinical trials in Alzheimer's disease in France (PO)